Effect of Testofen on Erectile Function in an Adult Male Population

Last updated: October 16, 2024
Sponsor: RDC Clinical Pty Ltd
Overall Status: Active - Recruiting

Phase

3

Condition

Male Hormonal Deficiencies/abnormalities

Infertility

Impotence

Treatment

Placebo comparator

Testofen 600mg

Testofen 300mg

Clinical Study ID

NCT05232279
TESTEF
  • Ages 40-75
  • Male

Study Summary

This is a double blind, randomised, placebo-controlled clinical study with a 12-week participation and 3 groups (2 active groups and 1 placebo group) designed to monitor erectile function symptom severity and the effect Testofen may have on improving erectile function, sexual function, and quality of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy male adults aged 40-75 years

  • Currently in a sexual relationship

  • Males with reduced erectile function (Score of <25 on IIEF)

  • BMI ≤ 35

  • Able to provide informed consent

  • Agree not to change current diet and exercise program while enrolled in this trial

  • Agree not to undertake another clinical trial while enrolled in this trial

Exclusion

Exclusion Criteria:

  • History of prostate surgery and/or trauma

  • Receiving/prescribed treatment for erectile dysfunction, including oral medications,vacuum devices, constrictive devices, injections, or urethral suppositories

  • Receiving/prescribed treatment to increase/decrease testosterone levels e.g.androgens/anti androgens

  • Receiving/prescribed treatment to increase/decrease nitrate or nitric oxide levels

  • Unstable or serious illness (e.g. serious mood disorders, neurological disorderssuch as MS, kidney disease, liver disease, heart conditions, diabetes, hormoneproduction disorders)*

  • All current malignancies (excluding BCC) or chemotherapy and/or radiotherapytreatment for malignancy within the previous 2 years

  • Receiving/prescribed [e.g., Coumadin or Marevan (warfarin), heparin, dalteparin,enoxaparin) or other anticoagulation therapy (e.g., thromboembolectomy or the use ofvena cava filters)

  • Active smokers, nicotine use, alcohol, or drug (prescription or illegal substances)abuse

  • Chronic past and/or current alcohol use (>14 alcoholic drinks week)

  • Allergic to any of the ingredients in the active or placebo formula

  • Any condition which in the opinion of the investigator makes the participantunsuitable for inclusion

  • Participants who have participated in any other related clinical study during thepast 1 month

a Any participant reporting having been told by their doctor that they have an under or over production of hormones (e.g., testosterone).

*An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.

Study Design

Total Participants: 120
Treatment Group(s): 3
Primary Treatment: Placebo comparator
Phase: 3
Study Start date:
April 19, 2022
Estimated Completion Date:
August 31, 2025

Connect with a study center

  • RDC Clinical Pty Ltd

    Brisbane, Queensland 4006
    Australia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.